ahlam1399
09-15-2016, 05:40 PM
BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint
* Merck and pfizer an**unce investigational Ertugliflozinmet primary endpoint of A1C reduction when added to Sitagliptinand Metformin in people with type 2 diabeteshttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=AjC3uvetcz0:TBFiNH7MEu8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=AjC3uvetcz0:TBFiNH7MEu8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=AjC3uvetcz0:TBFiNH7MEu8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=AjC3uvetcz0:TBFiNH7MEu8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=AjC3uvetcz0:TBFiNH7MEu8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/AjC3uvetcz0
* Merck and pfizer an**unce investigational Ertugliflozinmet primary endpoint of A1C reduction when added to Sitagliptinand Metformin in people with type 2 diabeteshttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=AjC3uvetcz0:TBFiNH7MEu8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=AjC3uvetcz0:TBFiNH7MEu8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=AjC3uvetcz0:TBFiNH7MEu8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=AjC3uvetcz0:TBFiNH7MEu8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=AjC3uvetcz0:TBFiNH7MEu8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/AjC3uvetcz0